Cargando…

Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment

Multidrug resistance (MDR) remains a major problem in cancer therapy and is characterized by the overexpression of p-glycoprotein (P-gp) efflux pump, upregulation of anti-apoptotic proteins or downregulation of pro-apoptotic proteins. In this study, an Apolipoprotein A1 (ApoA1)-modified cationic lip...

Descripción completa

Detalles Bibliográficos
Autores principales:	An, Duopeng, Yu, Xiaochen, Jiang, Lijing, Wang, Rui, He, Peng, Chen, Nanye, Guo, Xiaohan, Li, Xiang, Feng, Meiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956628/ https://www.ncbi.nlm.nih.gov/pubmed/33652957 http://dx.doi.org/10.3390/molecules26051280

Ejemplares similares

Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells
por: HUANG, FANG, et al.
Publicado: (2014)

Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8(+) T cells and the exclusion of Treg cells
por: Wang, Rui, et al.
Publicado: (2022)

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
por: Fracasso, P M, et al.
Publicado: (2005)

Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression
por: Huang, Yuan, et al.
Publicado: (2017)

Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen
por: Wang, He-Wen, et al.
Publicado: (2020)

Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
por: Minami, Hironobu, et al.
Publicado: (2001)

PEGylated Liposomes Remotely Loaded with the Combination of Doxorubicin, Quinine, and Indocyanine Green Enable Successful Treatment of Multidrug-Resistant Tumors
por: Grabarnick (Portnoy), Emma, et al.
Publicado: (2021)

Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin
por: Yokomichi, Noriyuki, et al.
Publicado: (2013)

Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance
por: Lei, Meng, et al.
Publicado: (2019)

Hollow MIL-125 Nanoparticles Loading Doxorubicin Prodrug and 3-Methyladenine for Reversal of Tumor Multidrug Resistance
por: Guo, Qingfeng, et al.
Publicado: (2023)

Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer
por: Cao, Lixia, et al.
Publicado: (2021)

Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
por: Lao, Juan, et al.
Publicado: (2013)

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma
por: Wei, Minyan, et al.
Publicado: (2015)

Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity
por: Wang, Wenxi, et al.
Publicado: (2017)

Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
por: Lian, Bo, et al.
Publicado: (2021)

Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity
por: Zhang, Tianyu, et al.
Publicado: (2023)

Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer
por: Wu, Debra, et al.
Publicado: (2020)

Reversal of multidrug resistance in human lung cancer cells by delivery of 3-octadecylcarbamoylacrylic acid–cisplatin-based liposomes
por: Song, Juan, et al.
Publicado: (2017)

Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance
por: Wang, Chunlei, et al.
Publicado: (2021)

Curcumin reverses doxorubicin resistance via inhibition the efflux function of ABCB4 in doxorubicin-resistant breast cancer cells
por: Wen, Chunjie, et al.
Publicado: (2019)

Poly(l-γ-glutamylglutamine) Polymer Enhances Doxorubicin Accumulation in Multidrug Resistant Breast Cancer Cells
por: Peng, Ting, et al.
Publicado: (2016)

Breviscapine reverses doxorubicin resistance in breast cancer and its related mechanisms
por: Fu, Weijiang, et al.
Publicado: (2023)

Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study
por: Davidson, Neville, et al.
Publicado: (2014)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer
por: Gu, Yue, et al.
Publicado: (2016)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
por: Franco, Yesenia L, et al.
Publicado: (2018)

Chondroitin Sulfate-Modified Liposomes for Targeted Co-Delivery of Doxorubicin and Retinoic Acid to Suppress Breast Cancer Lung Metastasis
por: Zhang, Zhiwei, et al.
Publicado: (2021)

Reversal of multidrug resistance by surfactants.
por: Woodcock, D. M., et al.
Publicado: (1992)

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
por: Zhang, Yue, et al.
Publicado: (2017)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Dual-Functional Peptide Driven Liposome Codelivery System for Efficient Treatment of Doxorubicin-Resistant Breast Cancer
por: Ahmed, Kamel S, et al.
Publicado: (2021)

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
por: Punt, C. J., et al.
Publicado: (1997)

Doxorubicin-loading core-shell pectin nanocell: A novel nanovehicle for anticancer agent delivery with multidrug resistance reversal
por: Ouyang, Jiabi, et al.
Publicado: (2020)

Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain
por: Tamaru, Mina, et al.
Publicado: (2014)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Screening of deoxyribozyme with high reversal efficiency against multidrug resistance in breast carcinoma cells
por: Gao, Peng, et al.
Publicado: (2011)

Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance
por: Wang, He, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_49q2g5del995halkob199sr6h5